Klacid Uno

Leaflet attached to the packaging: patient information

Warning! Keep the leaflet! Information on the immediate packaging in a foreign language.

Klacid Uno (Klacid SR), 500 mg, tablets with modified release

Clarithromycin
Klacid Uno and Klacid SR are different trade names for the same drug.

You should carefully read the contents of the leaflet before taking the medicine, as it contains important information for the patient.

• You should keep this leaflet, so that you can read it again if necessary.
• In case of any doubts, you should consult a doctor or pharmacist.
• This medicine has been prescribed specifically for one person. It should not be given to others. The medicine may harm another person, even if the symptoms of their illness are the same.
• If the patient experiences any side effects, including any side effects not listed in this leaflet, they should tell their doctor or pharmacist. See section 4.

Table of contents of the leaflet

• 1. What is Klacid Uno and what is it used for
• 2. Important information before taking Klacid Uno
• 3. How to take Klacid Uno
• 4. Possible side effects
• 5. How to store Klacid Uno
• 6. Contents of the packaging and other information

1. What is Klacid Uno and what is it used for

Klacid Uno contains the active substance clarithromycin. It is a macrolide antibiotic that inhibits the growth of bacteria that cause infections. The medicine is in the form of tablets with modified release. The tablet has been prepared in a special way and contains auxiliary substances that allow the modification of the speed and time of release of the active substance.
Klacid Uno is indicated for use in adults and children over 12 years of age for the treatment of infections caused by microorganisms sensitive to clarithromycin.
These infections include:

• upper respiratory tract infections (e.g. streptococcal pharyngitis, sinusitis),
• lower respiratory tract infections (e.g. bronchitis, pneumonia),
• acute otitis media,
• skin and soft tissue infections (e.g. infectious eczema, folliculitis, cellulitis, erysipelas, abscesses).

2. Important information before taking Klacid Uno

When not to take Klacid Uno

• If the patient is allergic to clarithromycin or other macrolide antibiotics (such as azithromycin, erythromycin) or any of the other ingredients of this medicine (listed in section 6).
• If the patient has severe renal impairment (creatinine clearance less than 30 ml/min), as there is no possibility of reducing the dose of the medicine (the tablets cannot be divided). In these patients, it is recommended to use Klacid in the form of immediate-release tablets.
• If the patient is taking ergot alkaloids, such as ergotamine or dihydroergotamine (used in migraine), or midazolam orally (used in anxiety and insomnia).
• If the patient is taking drugs that may cause severe heart rhythm disturbances.
• If the patient is taking astemizole or terfenadine (used in allergies), cisapride or domperidone (used in gastrointestinal disorders), pimozide (used in psychiatric disorders), as concomitant use with Klacid Uno may cause severe heart rhythm disturbances.
• If the patient is taking ticagrelor, ivabradine, or ranolazine (used in the treatment of angina or to reduce the risk of myocardial infarction or stroke).
• If the patient has low potassium or magnesium levels in the blood (hypokalemia or hypomagnesemia).
• If the patient is taking lovastatin or simvastatin (statins used to lower cholesterol levels in the blood).
• If the patient has severe liver impairment with concomitant renal impairment.
• If the patient or their family members have a history of heart rhythm disturbances (ventricular arrhythmias, including torsades de pointes) or electrocardiogram (ECG) abnormalities known as "long QT syndrome".
• If the patient is taking colchicine (used in the treatment of gout).
• If the patient is taking a medicine containing lomitapide.

Warnings and precautions

If the patient has any of the following conditions, they should discuss it with their doctor before starting treatment with Klacid Uno.

• The patient is pregnant or thinks they may be pregnant.
• The patient has kidney or liver function disorders.
• The patient has coronary artery disease, severe heart failure, or bradycardia.
• The patient is taking any of the medicines listed in the "Klacid Uno and other medicines" section.

If any of the following situations occur while taking Klacid Uno, the patient should tell their doctor.

• Severe allergic reactions, such as rash, urticaria, angioedema, anaphylaxis. The patient should immediately consult a doctor, who will provide appropriate treatment.
• Diarrhea, especially acute or prolonged. The patient should tell their doctor as soon as possible. If necessary, the doctor will prescribe appropriate treatment. The patient should not take anti-diarrheal medicines.
• Symptoms of liver function disorders, such as loss of appetite, jaundice, dark urine, itching, or abdominal pain. The patient should stop treatment and consult a doctor.
• New infections (superinfections) with bacteria resistant to clarithromycin or fungi, especially during long-term use of antibiotics. The doctor will prescribe appropriate treatment.

In addition, while taking Klacid Uno, the following may occur:

• Cross-resistance of bacteria (bacteria resistant to clarithromycin may also be resistant to other macrolide antibiotics and lincosamides and clindamycin).

If symptoms of damage to the ear or balance organ occur (see section 4), it is recommended to perform appropriate control tests after completing treatment.

Klacid Uno and other medicines

The patient should tell their doctor about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take.

The patient must inform their doctor if they are taking any of the following medicines, as their use with Klacid Uno is contraindicated:

• Ergot alkaloids, such as ergotamine or dihydroergotamine (used in migraine)
• Astemizole or terfenadine (used in allergies)
• Cisapride or domperidone (used in gastrointestinal disorders)
• Pimozide (used in psychiatric disorders)
• Ticagrelor, ranolazine (used in heart disease and circulation)
• Colchicine (used in gout)
• Statins - lovastatin, simvastatin (used to lower cholesterol levels in the blood)
• Midazolam orally (used in anxiety or insomnia).

The patient should inform their doctor if they are taking any of the following medicines, as special caution is required when using them with Klacid Uno:

Klacid Uno:

• Rifampicin, rifapentine, rifabutin (antibiotics used in the treatment of tuberculosis),
• Fluconazole, itraconazole (antifungal medicines),
• Atazanavir, efavirenz, etravirine, nevirapine, ritonavir, saquinavir, zidovudine (used in the treatment of HIV infection),
• Digoxin, quinidine, disopyramide, verapamil, amlodipine, diltiazem (used in the treatment of heart rhythm disorders or hypertension),
• Alprazolam, triazolam, midazolam administered intravenously or orally (used in anxiety or insomnia),
• Warfarin or other anticoagulant medicines, such as dabigatran, rivaroxaban, apixaban, edoxaban (used to thin the blood),
• Quetiapine or other atypical antipsychotic medicines,
• Carbamazepine, valproate, phenytoin (antiepileptic medicines),
• Methylprednisolone (anti-inflammatory medicine),
• Omeprazole (medicine that reduces stomach acid production),
• Cilostazol (used in intermittent claudication, which is characterized by leg pain during exercise and relieved by rest),
• Cyclosporine, tacrolimus, sirolimus (used in organ transplantation),
• Sildenafil, tadalafil, vardenafil (used in erectile dysfunction),
• Ibrutinib or vinblastine (used in chemotherapy for cancer),
• Theophylline (used in asthma),
• Tolterodine (used in urinary incontinence),
• Phenobarbital (antiepileptic medicine),
• St. John's Wort (herbal medicine used in mild depression),
• Sulfonylurea, nateglinide, repaglinide, insulin (used in diabetes).

This is also important if the patient is taking any of the following medicines:

• Hydroxychloroquine or chloroquine (used in the treatment of rheumatoid arthritis, or in the treatment or prevention of malaria). Taking these medicines with clarithromycin may increase the risk of heart rhythm disturbances and other serious side effects affecting the heart.
• Corticosteroids administered orally, by injection, or by inhalation (used to suppress the immune system, which is useful in the treatment of many different diseases).

Pregnancy and breastfeeding

If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a child, they should consult their doctor or pharmacist before taking this medicine.
The safety of clarithromycin during pregnancy and breastfeeding has not been established.
Klacid Uno may be used during pregnancy only if the doctor believes that the benefits to the mother outweigh the potential risks to the fetus.
Since clarithromycin passes into breast milk, breastfeeding women should exercise caution when taking Klacid Uno.

Driving and using machines

The medicine may cause dizziness, confusion, and disorientation, which may affect the ability to drive and operate machines.

Klacid Uno contains lactose monohydrate

If the patient has previously been diagnosed with intolerance to some sugars, they should contact their doctor before taking the medicine.

Klacid Uno contains sodium

The medicine contains 15.3 mg of sodium (the main component of table salt) per tablet. If the patient takes 2 tablets of Klacid Uno per day, the total amount of sodium ingested is 30.6 mg.
This corresponds to 1.5% of the maximum recommended daily intake of sodium in the diet for adults.

Klacid Uno contains quinoline yellow

Quinoline yellow (a dye) may cause allergic reactions in sensitive individuals.

3. How to take Klacid Uno

This medicine should always be taken as directed by the doctor. In case of doubts, the patient should consult their doctor or pharmacist.
The medicine is for oral use.
The tablet should be swallowed whole, with water. It should not be chewed, divided, or sucked.
Adults
The recommended dose is one 500 mg tablet, once a day, during a meal. In severe infections, the dose can be increased to 1 gram once a day (two 500 mg tablets). Treatment usually lasts 5 to 14 days. Only in the case of pneumonia or sinusitis should the medicine be taken for 6 to 14 days.
Children over 12 years of age
Dosing is the same as for adults.
Children under 12 years of age
Klacid oral suspension is recommended.
Patients with renal impairment
In patients with moderate renal impairment (creatinine clearance 30 to 60 ml/min), the dose of the medicine should be reduced by half, i.e., to a maximum of 1 tablet of Klacid Uno per day.
In patients with severe renal impairment (creatinine clearance less than 30 ml/min), Klacid Uno is contraindicated, as there is no possibility of reducing the dose (the tablets cannot be divided).
In these patients, it is recommended to use a medicine containing clarithromycin with immediate release.

Taking a higher dose of Klacid Uno than recommended

In case of taking a higher dose of Klacid Uno than recommended, the patient should immediately consult their doctor or pharmacist.
Taking a higher dose of Klacid Uno than recommended by the doctor may cause gastrointestinal symptoms (vomiting, abdominal pain).

Missing a dose of Klacid Uno

In case of missing a dose of Klacid Uno, the patient should take it as soon as possible, and then take the next dose at the scheduled time.
The patient should not take a double dose to make up for the missed dose.

Stopping treatment with Klacid Uno

In case of any further doubts about the use of this medicine, the patient should consult their doctor or pharmacist.
The patient should not stop treatment, even if they feel better and the symptoms of the disease have disappeared after a few days of taking the medicine.

4. Possible side effects

Like all medicines, Klacid Uno can cause side effects, although not everyone gets them.

If the patient experiences any of the following side effects, they should stop taking Klacid Uno and consult their doctor immediately:

• Anaphylactic shock - a life-threatening allergic reaction, characterized by confusion, pale skin, low blood pressure, sweating, decreased urine production, rapid breathing, weakness, and fainting.
• Allergic reactions: rash (frequent), itching, urticaria (not very frequent), angioedema of the face, tongue, lips, eyes, and throat, difficulty breathing.
• Severe skin reactions:
• Acute generalized exanthematous pustulosis - a red, scaly rash with bumps under the skin and blisters.
• Stevens-Johnson syndrome, characterized by sudden onset of fever and blisters that heal quickly and spontaneously after discontinuation of the medicine; a severe disease characterized by blisters and ulcers on the skin, in the mouth, eyes, and genitals, fever, and joint pain.
• Toxic epidermal necrolysis - a severe, rapidly progressing disease characterized by large, bursting blisters under the skin, extensive ulcers on the skin, shedding of large skin flakes, and fever.
• DRESS syndrome - a severe (life-threatening) drug rash that occurs with an increased number of eosinophils and involvement of internal organs.
• Severe or prolonged diarrhea, possibly with blood or mucus in the stool (pseudomembranous colitis). Diarrhea may occur even two months after completing treatment with clarithromycin. In such cases, the patient should also consult their doctor.
• Jaundice, skin irritation, light-colored stools, dark urine, abdominal tenderness, or loss of appetite. These may be symptoms of liver failure.
• Muscle swelling, cramps, and pain, which may be symptoms of rhabdomyolysis (a syndrome of disease symptoms caused by muscle tissue breakdown). In some cases of rhabdomyolysis, clarithromycin was administered concomitantly with other medicines known to cause rhabdomyolysis, such as lipid-lowering agents (e.g., statins, fibrates) or gout medicines (e.g., colchicine or allopurinol). These reactions occur with an unknown frequency, unless otherwise specified.

Other side effects

In clinical trials and after the introduction of clarithromycin to the market, the following side effects were frequentlyreported (occurring in 1 to 10 out of 100 patients):

• Insomnia,
• Taste disorders, headache,
• Diarrhea, vomiting, nausea, abdominal pain,
• Abnormal liver function test results,
• Excessive sweating.

Side effects reported not very frequently(occurring in 1 to 10 out of 1000 patients):

• Candidiasis (fungal infection), gastritis, vaginal infection,
• Decreased white blood cell count,
• Hypersensitivity,
• Anorexia, decreased appetite,
• Anxiety,
• Dizziness, drowsiness, tremors,
• Balance disorders, hearing loss, tinnitus,
• Palpitations, changes in ECG (QT interval prolongation),
• Nosebleeds,
• Gastroesophageal reflux disease, gastritis, proctitis, stomatitis, glossitis, constipation, dry mouth, belching, bloating with gas release,
• Increased activity of liver enzymes: alanine aminotransferase (ALT), aspartate aminotransferase (AST),
• Muscle pain,
• Asthenia (weakness, lack of strength).

The following side effects have been reported with an unknown frequency(frequency cannot be estimated from available data) after the introduction of Klacid tablets and oral suspension to the market:

• Rosacea,
• Agranulocytosis (decreased granulocyte count in the blood), thrombocytopenia (decreased platelet count),
• Acne,
• Psychotic disorder, confusion, depersonalization, depression, disorientation, hallucinations, unusual dreams, mania,
• Seizures, loss of taste, abnormal smell, loss of smell, paresthesia (numbness, tingling),
• Deafness,
• Heart rhythm disorders, such as torsades de pointes, ventricular tachycardia, atrial fibrillation,
• Bleeding,
• Acute pancreatitis, tongue discoloration, tooth discoloration,
• Myopathy (muscle disease with muscle weakness),
• Kidney failure, interstitial nephritis,
• Changes in diagnostic test results (increased international normalized ratio (INR), prolonged prothrombin time, abnormal urine color).

Patients with impaired immune function
In addition to symptoms related to the course of the disease, the following side effects have been observed in adult patients with impaired immune function:

• Nausea, vomiting, changes in taste, constipation, abdominal pain, diarrhea, bloating with gas release, dry mouth,
• Headache, hearing disorders,
• Rash,
• Dyspnea, insomnia,
• Abnormal laboratory test results: increased aspartate aminotransferase (AST) and alanine aminotransferase (ALT) activity, increased blood urea nitrogen levels, and decreased platelet and white blood cell counts.

Reporting side effects

If the patient experiences any side effects, including any side effects not listed in the leaflet, they should tell their doctor or pharmacist. Side effects can be reported directly to the Department of Adverse Reaction Monitoring of Medicinal Products, Medical Devices, and Biocidal Products,
Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309,
website: https://smz.ezdrowie.gov.pl
By reporting side effects, more information can be collected on the safety of the medicine.

5. How to store Klacid Uno

The medicine should be stored out of sight and reach of children.
The medicine should not be used after the expiration date stated on the packaging. The expiration date refers to the last day of the specified month.
Store at a temperature below 30°C. Store in the original packaging to protect from light.
Medicines should not be disposed of in wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.

6. Contents of the packaging and other information

What Klacid Uno contains

• The active substance of the medicine is clarithromycin. One modified-release tablet contains 500 mg of clarithromycin.
• The other ingredients are: citric acid, sodium alginate, sodium-calcium alginate, lactose monohydrate, povidone 40, talc, stearic acid 95%, magnesium stearate; coating ingredients: hypromellose, macrogol 400, macrogol 8000, titanium dioxide (E 171), quinoline yellow (aluminum lake), sorbic acid.

What Klacid Uno looks like and what the packaging contains

Klacid Uno is available in the form of modified-release tablets.
The tablet is yellow, oval in shape.
The packaging contains: 7 tablets in 1 blister pack.
PVC/PVDC/Al blisters in a cardboard box.
For more detailed information, the patient should contact the marketing authorization holder or parallel importer.

Marketing authorization holder in the Czech Republic, the country of export:

Viatris Healthcare Limited
Damastown Industrial Park
Mulhuddart, Dublin 15
Dublin, Ireland

Manufacturer:

AbbVie S.r.l., Via Pontina, km 52, 04011 Campoverde di Aprilia (LT), Italy

Parallel importer:

InPharm Sp. z o.o.
ul. Strumykowa 28/11
03-138 Warsaw

Repackaged by:

InPharm Sp. z o.o. Services sp. k.
ul. Chełmżyńska 249
04-458 Warsaw
Marketing authorization number in the Czech Republic, the country of export:15/062/98-C
Parallel import authorization number:402/14

Date of leaflet approval: 25.11.2024

[Information about the trademark]